Neoadjuvant camrelizumab plus chemotherapy in locally advanced oesophageal squamous cell carcinoma: a retrospective cohort study

Abstract Background Neoadjuvant therapy is recommended to improve the prognosis of oesophageal squamous cell carcinoma (ESCC). As a PD-1 inhibitor developed in China, camrelizumab is more accessible and available for Chinese ESCC patients. Camrelizumab plus neoadjuvant chemotherapy has shown promisi...

Full description

Bibliographic Details
Published in:BMC Surgery
Main Authors: Rui-Qin Zhou, Jun Luo, Lin-Jun Li, Ming Du, Qing-Chen Wu
Format: Article
Language:English
Published: BMC 2023-05-01
Subjects:
Oesophageal squamous cell carcinoma (ESCC)
Neoadjuvant chemotherapy
Immunotherapy
Camrelizumab
Docetaxel
Nedaplatin
Online Access:https://doi.org/10.1186/s12893-023-02023-5

Internet

https://doi.org/10.1186/s12893-023-02023-5

Similar Items